Last Updated: November 11, 2026
IV Ketamine for Depression: Is It Really the Gold Standard?
Ketamine therapy is one of the fastest-acting treatments for depression. IV infusions have the longest research history, but a longer research history does not make IV the most effective form, and many of the assumptions behind its gold-standard reputation do not hold up. Real-world results for at-home ketamine land in the same range, and the practical differences between forms are large. This article breaks down what "gold standard" actually means, how IV compares with other forms of ketamine on real-world results, and how cost, convenience, and support factor in.
Key takeaways
- Ketamine therapy is one of the fastest-acting treatments for depression. In one at-home study, 70% saw meaningful relief within about two weeks.¹ Standard antidepressants usually take four to eight weeks.²
- IV has the largest base of randomized trials, which is a big part of why it is called the gold standard. No guideline or regulator formally gives it that title.³
- More trials does not mean more people. The two largest reviews of ketamine research cover fewer than 6,000 people combined.⁴⁻⁵ One at-home sublingual study followed 11,441.⁶
- On the same PHQ-9 measure, real-world results for IV and sublingual ketamine land in a similar range.⁶⁻⁷ Subcutaneous results do too.¹ Individual results may vary.
- The forms differ most in setting, cost, and support. For many people, those practical factors decide which form fits best.
Is IV Ketamine the Gold Standard for Depression?
No. IV is widely assumed to be the gold standard of ketamine therapy, but on the measures that matter most, the data does not support that assumption:
- Recognition: No guideline or regulator has named IV the gold standard.
- Outcomes: On the same PHQ-9 depression measure, real-world results for at-home ketamine are comparable to IV.⁶⁻⁷
- People studied: IV has the most trials, but not the most patients studied, as the section below shows.
- Practicality: IV means repeated clinic visits, and insurance may not cover it.⁸
IV leads in the size of its evidence base, not in outcomes. The 2026 consensus guidelines from the American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3) focus on IV because "this indication and route have the most robust evidence base for efficacy, safety, and clinical procedures" (ASKP3, 2026).³ That describes how much research exists, not a finding that IV works better.
What "Gold Standard" Means in Depression Treatment
In medicine, a gold standard is the reference treatment other options are measured against. For IV to hold that title within ketamine therapy, it would need to clear four bars:
- Guideline endorsement: Guidelines name it the preferred form of ketamine.
- Regulatory approval: The FDA has approved it for depression.
- Comparative evidence: Head-to-head trials show it does better than other forms.
- Long-term data: Studies follow patients for months or years.
The evidence that IV ketamine works is strong. What it lacks is evidence that it works better than other forms. Some guidelines grade the evidence for IV more highly than for other forms, but none names it the gold standard, and large head-to-head trials against other forms have not been done. ASKP3's authors also note that "long-term efficacy and safety data are considerably more extensive for intranasal esketamine than for IV racemic ketamine."³
Even a treatment that cleared all four bars would not be the best choice for everyone. Travel, time, cost, and support all shape that decision.
Why IV Ketamine Became the Research Benchmark
IV became the research benchmark by default, largely for practical and historical reasons rather than evidence that it treats depression better.
- It was already given that way. Ketamine has been FDA-approved as an anesthetic since 1970, given by IV or by injection into a muscle (FDA, KETALAR label).⁹ Researchers started with the route hospitals already used. That route was chosen for anesthesia, not because anyone had compared it with other routes for depression.
- The first trial set the template. The first controlled study of ketamine for depression gave seven patients a single IV dose and compared it with a saline infusion (Berman et al., 2000).¹⁰ Later trials largely kept that design, so their results could be compared.
- Research builds on research. Each new IV study made the next one easier to design and compare, so the evidence base grew around one route.
None of those reasons show that IV works better for depression. They explain why there is more IV research, not why IV would produce better results.
Has IV Ketamine Been Studied on the Most People?
No. You might expect the gold standard of ketamine therapy to be the form studied on the most people. It is not. IV has the most individual studies, but more studies is not the same as more patients.
| Body of research | What it covers | People |
|---|---|---|
| Largest review of ketamine clinical trials (Nikolin et al., 2023) | 49 randomized trials of ketamine and esketamine, all routes | 3,299⁴ |
| Largest review of real-world ketamine studies (Alnefeesi et al., 2022) | 79 real-world studies, mostly IV | 2,665⁵ |
| Largest single real-world IV study (McInnes et al., 2022) | 178 community practices across the US | 537 with outcome data (from 9,016 records)⁷ |
| At-home sublingual ketamine (Mathai et al., 2024) | One real-world study of Mindbloom clients | 11,441⁶ |
| At-home subcutaneous ketamine (Parks et al., 2026) | One real-world study of Mindbloom clients | 3,041¹ |
Put together, the two largest reviews cover fewer than 6,000 people, and both include forms of ketamine besides IV. A single study of at-home sublingual ketamine followed nearly twice that many.
IV does still have far more randomized controlled trials, the design best suited to proving a treatment beats placebo. What it does not have is the largest body of real-world data from routine care. Studying a treatment on more people does not by itself make it work better, but it does mean the assumption behind the gold-standard label does not match the published record.
How Does IV Ketamine Compare to Other Forms of Ketamine?
On the same PHQ-9 depression questionnaire, real-world results for IV, sublingual, and subcutaneous ketamine therapy for depression land in the same range.
| Real-world ketamine, mostly IV (pooled review) | Real-world IV (largest single study) | At-home sublingual (Mindbloom) | At-home subcutaneous (Mindbloom) | |
|---|---|---|---|---|
| Study | Alnefeesi et al., 2022⁵ | McInnes et al., 2022⁷ | Mathai et al., 2024⁶ | Parks et al., 2026¹ |
| People | 2,665 (79 studies) | 537 | 11,441 | 3,041 |
| Response | About 45% | 53.6% | 56.4% | 56.6% |
| Remission | About 30% | 28.9% | 28.1% | 27.7% |
| Measure | Various scales | PHQ-9 | PHQ-9 | PHQ-9 |
| When measured | Varies by study | 2 to 4 weeks after the infusion series | End of 4-session course | End of 6-session course |
Response means symptoms fell by at least half. Remission means symptoms fell to minimal levels. The pooled review enrolled only people with treatment-resistant depression, and the Mindbloom studies enrolled adults with moderate to severe symptoms. No trial has compared these forms head to head, so read the figures as a range rather than a ranking.
IV Ketamine vs. Esketamine (Spravato)
Standard (racemic) ketamine is made of two mirror-image forms. Esketamine is one of them, given as a nasal spray (Spravato) in a certified health care setting, and it is the only form of ketamine FDA-approved for depression (FDA, SPRAVATO label).¹¹
Head-to-head evidence is limited. A 2025 meta-analysis of seven observational studies that compared the two directly found similar response and remission rates, with IV possibly working faster (Elmosalamy et al., 2025).¹² A 2021 meta-analysis of 24 trials, which compared each against placebo or a control, found racemic ketamine produced greater response and remission than esketamine (Bahji et al., 2021).¹³
These studies compared IV ketamine with esketamine nasal spray. None included at-home care, so they do not show IV outperforming at-home programs. Esketamine's advantages include FDA approval, more frequent insurance coverage, and more extensive long-term data.³
IV Ketamine vs. At-Home Ketamine
At-home ketamine programs vary by provider. Mindbloom, the largest provider of guided at-home ketamine therapy with more than 900,000 clinician-supervised sessions as of November 2026, offers sublingual tablets and is the only at-home provider of subcutaneous injections. Here is how its published outcomes compare with the largest real-world IV study, which reported 53.6% response and 28.9% remission (McInnes et al., 2022):⁷
- Sublingual, largest study: In Mindbloom's largest study, 11,441 clients reached 56.4% response and 28.1% remission, comparable to IV (Mathai et al., 2024).⁶
- Subcutaneous: In its study of at-home subcutaneous ketamine, 3,041 clients reached 56.6% response and 27.7% remission, comparable to or slightly exceeding IV on response (Parks et al., 2026).¹
- Sublingual, first study: Mindbloom's first outcomes study, an earlier and smaller study of 1,247 clients, reported 62.8% response and 32.6% remission (Hull et al., 2022).¹⁴
Individual results may vary. For more, see this guide to sublingual ketamine compared with IV.
What Do Clinical Guidelines and the FDA Say About IV Ketamine?
Guidelines support ketamine as a treatment for depression. None names IV the gold standard or shows that it produces better outcomes than other forms.
| Source | Position on ketamine | Names IV the gold standard? |
|---|---|---|
| ASKP3 consensus guidelines (US, 2026) | Sets standards for safe IV practice; covers IV because it has the most robust evidence base, and notes evidence for other routes is still mainly observational³ | No |
| CANMAT task force (Canada, 2021) | Grades evidence for IV ketamine more highly than for oral and other non-IV forms; lists IV as a third-line option¹⁵ | No |
| VA/DoD depression guideline (2022) | Suggests ketamine or esketamine as an add-on option for people who have not responded to several medication trials¹⁶ | No; groups ketamine and esketamine together |
| VA Community Care criteria (2026) | Covers IV ketamine for eligible Veterans with treatment-resistant depression¹⁷ | No |
| NICE (UK, 2026) | Has not added IV ketamine to its depression guideline; notes that guidelines in Australia, New Zealand, Canada, and Norway recommend it¹⁸ | No |
| FDA | Approved esketamine nasal spray for depression; generic ketamine is approved as an anesthetic and used off-label for depression⁹ | No |
Is IV Ketamine FDA Approved for Depression?
Generic (racemic) ketamine, in every form including IV, tablets, and injections, is prescribed off-label for depression. Off-label means a licensed clinician uses an FDA-approved drug for a purpose not listed on its label. It is a statement about regulatory status, not about whether a treatment works, and it is common: in one national study using 2001 data, about one in five uses of 160 commonly prescribed drugs were off-label (Radley et al., 2006).¹⁹
Esketamine nasal spray was approved in 2019 for treatment-resistant depression alongside an oral antidepressant.¹¹ A 2020 approval added depression with acute suicidal thoughts or behavior.²⁰ In January 2025, the FDA approved it as a standalone treatment for treatment-resistant depression.²¹
IV Ketamine vs. At-Home Ketamine: Logistics, Cost, and Support
When results are comparable, practical differences often decide which form is best for a given person. IV means repeated trips to a clinic, while at-home care happens from the comfort of home.
| IV ketamine | Esketamine (Spravato) | At-home ketamine (Mindbloom) | |
|---|---|---|---|
| Where | Clinic | Certified health care setting | Home |
| Time per visit | About 2 hours, including a 40-minute infusion and recovery¹⁷ | At least 2 hours of on-site monitoring after each dose²² | Session at home, no travel |
| Getting home | You can't drive yourself home²³ | You can't drive until the next day²² | No travel needed |
| Schedule | Typically 4 to 6 infusions over 2 to 4 weeks³ | Twice a week for the first 4 weeks²² | Programs of 6, 12, or 18 sessions |
| Preparation and integration | Not standard; varies by clinic²⁴ | Not required by the FDA label²² | Included in every program |
| Typical self-pay cost | $400 to $800+ per infusion²⁵ | Varies; often covered by insurance³ | $165 to $215 per session |
| Insurance | May not be covered⁸ | More often covered | HSA/FSA eligible; Superbill for possible reimbursement |
What an IV Ketamine Treatment Course Involves
A typical course of ketamine infusion for depression starts with a medical and psychiatric evaluation, then an induction series of about four to six infusions.³ In the VA's national protocol, each infusion of 0.5 mg/kg runs over 40 minutes, up to twice a week for four weeks, followed by spaced-out maintenance for people who respond (VA Pharmacy Benefits Management, 2025).²³ Each visit means arranging time off, travel, and a ride home.
Why Preparation and Integration Matter
Integration is the work of making sense of a session and carrying what surfaced into daily life. In one randomized trial, patients who added structured psychological work after ketamine kept their improvement significantly better than those who had ketamine alone (Wilkinson et al., 2021).²⁶
With IV, that support is not a standard part of care. Consensus statements on standard IV administration cover the setting, vital-sign monitoring, and observation until the person is stable, with no integration component (Sanacora et al., 2017).²⁴ Some clinics include preparation and integration in their packages, while others sell it as an add-on or refer out, so what you get depends on the clinic. Mindbloom includes preparation and integration coaching in every program. For more, see how integration affects ketamine therapy outcomes.
What Side Effects Can Occur
The types of side effects are similar across forms of ketamine, and they usually fade within a couple of hours: dissociation (a dreamlike or detached feeling), a temporary rise in blood pressure, nausea, dizziness, and headache. Providers check blood pressure before each session for this reason.³ In Mindbloom's sublingual study, serious adverse events occurred in 0.05% of clients.⁶ In its subcutaneous study, the rate was 0.08%.¹ See our full guide to ketamine side effects.
How Much Does IV Ketamine Cost, and Does Insurance Cover It?
IV ketamine infusions typically cost $400 to $800 or more per session, depending on the clinic.²⁵ At that rate, a six-infusion series runs about $2,400 to $4,800 before any maintenance sessions. That cost is often paid out of pocket, since insurance may not cover IV ketamine, as PCORI's patient evidence update notes.⁸ The VA covers IV ketamine for eligible Veterans.¹⁷ Ask your insurer and the clinic about the total cost of a course before you start.
Mindbloom's new-client pricing runs $165 to $215 per session, depending on program length. Programs are HSA/FSA eligible, and a Superbill may allow partial reimbursement, though amounts are not guaranteed. Learn more about ketamine therapy cost and reimbursement, or see whether Mindbloom's depression program is a fit.
Important Safety Information
Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information
Off-Label Use Disclosure
Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.
Frequently asked questions
Is Ketamine Only for Treatment-Resistant Depression?
Most research and guidelines focus on treatment-resistant depression, but clinicians may consider ketamine therapy for adults with depression, anxiety, or PTSD when it is medically appropriate.
How Quickly Can IV Ketamine Ease Depression Symptoms?
In clinical trials, IV ketamine has eased symptoms within hours. At-home ketamine is fast too: in Mindbloom's subcutaneous study, most clients saw meaningful relief by their second session, about two weeks in, which was the first point measured.
How Does Ketamine Compare to ECT?
In the largest head-to-head trial, ketamine was at least as effective as ECT for nonpsychotic treatment-resistant depression, with fewer short-term memory effects. ECT remains an important option for severe depression.
How Does Ketamine Compare to TMS?
Ketamine works faster, often within days, while TMS builds over weeks of near-daily clinic visits. Studies have found similar response rates between the two.
Do You Need Maintenance Treatments After Ketamine?
Not always. Guidelines suggest maintenance may be considered case by case for people who improve and face a risk of relapse. In Mindbloom's largest study, most clients who improved and chose a second course maintained or regained that improvement.
Who May Not Be a Good Candidate for IV Ketamine?
Ketamine may not be appropriate for people with uncontrolled high blood pressure, a history of psychosis, or an active substance use disorder, among other conditions. A licensed provider evaluates these factors before treatment.
Can You Switch From IV Ketamine to At-Home Ketamine?
Yes, if a licensed clinician determines it is medically appropriate. At-home programs differ in route, monitoring, and support, so ask each provider how they handle dosing and follow-up.
Mindbloom Treatment
See what might be possible with clinician-guided, at-home ketamine therapy. New client programs start at $165 per session.
Authors
